Posted by Michael Wonder on 07 Dec 2021
Zai Lab announces inclusion of Zejula (niraparib) in China’s National Reimbursement Drug List for first-line ovarian cancer
3 December 2021 - Zai Lab today announced that the National Reimbursement Drug List released by China’s National Healthcare Security Administration has been updated to include Zejula (niraparib) as a first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (collectively termed as ovarian cancer) following a response to platinum-based chemotherapy, regardless of biomarker status.
In December 2020, Zejula was included in the National Reimbursement Drug List as a maintenance treatment of adult patients with platinum-sensitive, recurrent ovarian cancer.
